Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 1, 2008, Pages 225-236

  Buckheit Jr , Robert W ^a   Hartman, Tracy L ^a   Watson, Karen M ^a   Chung, Sun Gan ^b   Cho, Eui Hwan ^b  

^a ImQuest Biosciences   (United States)

^b Samil Pharmaceutical Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CYCLOPENTENYLMETHYL) 6 (3,5 DIMETHYLBENZOYL) 5 ETHYLURACIL; 1 (3 CYCLOPENTENYLMETHYL) 6 (3,5 DIMETHYLBENZOYL) 5 ETHYLURACIL DERIVATIVE; PYRIMIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; HELA CELLS; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-2; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIDONES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 37849003124     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00972-07     Document Type: Article

References (50)

1. Baba, M., S. Shigeta, H. Tanaka, T. Miyasaka, M. Ubasawa, K. Umezu, R. T. Walker, R. Pauwels, and E. De Clercq. 1992. Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives. Antivir. Res. 17:245-264.
2. Baba, M., S. Shigeta, S. Yuasa, H. Takashima, K. Sekiya, M. Ubasawa, H. Tanaka, T. Miyasaka, R. T. Walker, and E. De Clercq. 1994. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 38:688-692.
3. Baba, M., H. Tanaka, E. De Clercq, R. Pauwels, J. Balzarini, D. Schols, H. Nakashima, C. F. Perno, R. T. Walker, and T. Miyasaka. 1989. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 165:1375-1381.
4. Boyer, P. L., M. J. Currens, J. B. McMahon, M. R. Boyd, and S. H. Hughes. 1993. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 67:2412-2420.
5. Buckheit, R. W., Jr. 2004. Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy. Expert Opin. Investig. Drugs 13:933-958.
6. Buckheit, R. W., Jr., V. Fliakas-Boltz, W. D. Decker, J. L. Roberson, T. L. Stup, C. A. Pyle, E. L. White, J. B. McMahon, M. J. Currens, M. R. Boyd, et al. 1995. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antivir. Res. 26:117-132.
7. Buckheit, R. W., Jr., V. Fliakas-Boltz, S. Yeagy-Bargo, O. Weislow, D. L. Mayers, P. L. Boyer, S. H. Hughes, B. C. Pan, S. H. Chu, and J. P. Bader. 1995. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. Virology 210:186-193.
8. Buckheit, R. W., Jr., T. L. Hartman, K. M. Watson, H. S. Kwon, S. H. Lee, J. W. Lee, D. W. Kang, S. G. Chung, and E. H. Cho. 2007. The structure-activity relationships of 2,4 (1H, 3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors. Antivir. Chem. Chemother. 18:259-275.
9. Buckheit, R. W., Jr., T. L. Kinjerski, V. Fliakas-Boltz, J. D. Russell, T. L. Stup, L. A. Pallansch, W. G. Brouwer, D. C. Dao, W. A. Harrison, R. J. Schultz, et al. 1995. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type 1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 39:2718-2727.
10. Buckheit, R. W., Jr., J. L. Roberson, C. Lackman-Smith, J. R. Wyatt, T. A. Vickers, and D. J. Ecker. 1994. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum Retrovir. 10:1497-1506.
11. Buckheit, R. W., Jr., K. Watson, V. Fliakas-Boltz, J. Russell, T. L. Loftus, M. C. Osterling, J. A. Turpin, L. A. Pallansch, E. L. White, J.-W. Lee, S.-H. Lee, J.-W. Oh, H.-S. Kwon, S.-G. Chung, and E.-H. Cho. 2001. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob. Agents Chemother. 45:393-400.
12. Carpenter, C. C., D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 2000. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283:381-390.
13. Ciminale, V., B. K. Felber, M. Campbell, and G. N. Pavlakis. 1990. A bioassay for HIV-1 based on Env-CD4 interaction. AIDS Res. Hum Retrovir. 6:1281-1287.
14. Danel, K., E. Larsen, E. B. Pedersen, B. F. Vestergaard, and C. Nielsen. 1996. Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 39:2427-2431.
15. De Clercq, E. 1995. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8:200-239.
16. De Clercq, E. 2004. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem. Biodivers. 1:44-64.
17. De Clercq, E. 1999. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco 54:26-45.
18. Deeks, S. G., M. Smith, M. Holodniy, and J. O. Kahn. 1997. HIV-1 protease inhibitors. A review for clinicians. JAMA 277:145-153.
19. Ding, J., K. Das, C. Tantillo, W. Zhang, A. D. Clark, Jr., S. Jessen, X. Lu, Y. Hsiou, A. Jacobo-Molina, K. Andries, et al. 1995. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution. Structure 3:365-379.
20. Dolle, V., E. Fan, C. H. Nguyen, A. M. Aubertin, A. Kirn, M. L. Andreola, G. Jamieson, L. Tarrago-Litvak, and E. Bisagni. 1995. A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors. J. Med. Chem. 38:4679-4686.
21. Dorr, P., M. Westby, S. Dobbs, P. Griffin, B. Irvine, M. Macartney, J. Mori, G. Rickett, C. Smith-Burchnell, C. Napier, R. Webster, D. Armour, D. Price, B. Stammen, A. Wood, and M. Perros. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732.
22. Fischl, M. A, D. D. Richman, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, R. T. Schooley, et al. 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317:185-191.
23. Foley, G. E., H. Lazarus, S. Farber, B. G. Uzman, B. A. Boone, and R. E. McCarthy. 1965. Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18:522-529.
24. Hostomsky, Z., Z. Hostomska, T. B. Fu, and J. Taylor. 1992. Reverse transcriptase of human immunodeficiency virus type 1: functionality of subunits of the heterodimer in DNA synthesis. J. Virol. 66:3179-3182.
25. Kim, D.K., J. Gam, Y.-W. Kim, J. Lim, H.-T. Kim, and K.-H. Kim. 1996. Synthesis and anti-HIV-1 activity of a series of 1-(alkoxymethyl)-5-alkyl- 6-(arylselencnyl)uracils and -2-thiouracils. Heterocyclic Chem. 14:1275-1282.
26. Kimpton, J., and M. Emerman. 1992. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 66:2232-2239.
27. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
28. Lederer, H., O. Schatz, R. May, H. Crespi, J. L. Darlix, S. F. Le Grice, and H. Heumann. 1992. Domain structure of the human immunodeficiency virus reverse transcriptase. EMBO J. 11:1131-1139.
29. Le Grice, S. F., T. Naas, B. Wohlgensinger, and O. Schatz. 1991. Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase. EMBO J. 10:3905-3911.
30. Mai, A., M. Artico, G. Sbardella, S. Massa, E. Novellino, G. Greco, A. G. Loi, E. Tramontano, M. E. Marongiu, and P. La Colla. 1999. 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3 H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives. J. Med. Chem. 42:619-627.
31. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
32. Miyasaka, T., H. Tanaka, M. Baba, H. Hayakawa, R. T. Walker, J. Balzarini, and E. De Clercq. 1989. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32:2507-2509.
33. Mocroft, A., S. Vella, T. L. Benfield, A. Chiesi, V. Miller, P. Gargalianos, A. d'Arminio Monforte, I. Yust, J. N. Bruun, A. N. Phillips, and J. D. Lundgren for the EuroSIDA Study Group. 1998. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 352:1725-1730.
34. Nara, P. L., and P. J. Fischinger. 1988. Quantitative infectivity assay for HIV-1 and -2. Nature 332:469-470.
35. Nara, P. L., W. C. Hatch, N. M. Dunlop, W. G. Robey, L. O. Arthur, M. A. Gonda, and P. J. Fischinger. 1987. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res. Hum Retrovir. 3:283-302.
36. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg for the HIV Outpatient Study Investigators. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
37. Parker, W. B., E. L. White, S. C. Shaddix, L. J. Ross, R. W. Buckheit, Jr., J. M. Germany, J. A. Secrist III, R. Vince, and W. M. Shannon. 1991. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine and 3′-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs. J. Biol. Chem. 266:1754-1762.
38. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
39. Ratner, L., W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E. A. Whitehorn, K. Baumeister, et al. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277-284.
40. Richman, D. D. 1996. HIV therapeutics. Science 272:1886-1888.
41. Salter, R. D., D. N. Howell, and P. Cresswell. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235-246.
42. Starcich, B. R., B. H. Hahn, G. M. Shaw, P. D. McNeely, S. Modrow, H. Wolf, E. S. Parks, W. P. Parks, S. F. Josephs, R. C. Gallo, et al. 1986. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45:637-648.
43. Szczech, G. M., P. Furman, G. R. Painter, D. W. Barry, K. Borroto-Esoda, T. B. Grizzle, M. R. Blum, J. Sommadossi, R. Endoh, T. Niwa, M. Yamamoto, and C. Moxham. 2000. Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:123-130.
44. Trabattoni, D., S. Lo Caputo, M. Biasin, E. Seminari, M. Di Pietro, G. Ravasi, F. Mazzotta, R. Maserati, and M. Clerici. 2002. Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin. Diagn. Lab. Immunol. 9:1114-1118.
45. UNAIDS. 2004. UNAIDS Executive Summary 2004 Report on the Global AIDS Epidemic. UNAIDS/04.16E. UNAIDS (Joint United Nations Programme on HIV/AIDS), Geneva, Switzerland. http://www.unaids.org/bangkok2004/GAR2004_pdf/ GAR2004_ExecSumm_en.pdf.
46. UNAIDS/WHO. 2006. AIDS epidemic update: December 2006. UNAIDS/06.29E. UNAIDS (Joint United Nations Programme on HIV/AIDS) and World Health Organization (WHO). UNAlDS, Geneva, Switzerland. http://data.unaids.org/ pub/EpiReport/2006/2006_EpiUpdate_en.pdf.
47. U.S. Food and Drug Administration. 2007. Drugs used in the treatment of HIV infection. http://www.fda.gov/oashi/aids/virals.html. Accessed 15 October 2007.
48. White, E. L., W. B. Parker, L. J. Ross, and W. M. Shannon. 1993. Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogs. Antivir. Res. 22:295-308.
49. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.
50. Yeni, P. G., S. M. Hammer, M. S. Hirsch, M. S. Saag, M. Schechter, C. C. Carpenter, M. A. Fischl, J. M. Gatell, B. G. Gazzard, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2004. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292:251-265.